Form 4: Nurix Therapeutics Chief Legal Officer Christine Ring Reports Stock Option Exercise and Sale
SEC Form 4
Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on November 1, 2024, according to a Form 4 filing with the SEC.
Summary
- On November 1, 2024, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, exercised stock options to acquire 5,760 shares of common stock at a price of $1.86 per share.
- Simultaneously, she sold 5,760 shares of common stock at a weighted average price of $24.2824 per share, with prices ranging from $23.99 to $24.65.
- Following these transactions, Ring directly owns 28,084 shares of Nurix Therapeutics common stock and holds options for 65,506 shares.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. The transactions appear to be part of a pre-planned strategy, and there's no indication of unusual or concerning activity.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like Rule 10b5-1, which allows insiders to trade without being accused of acting on non-public information.
Comparison to Industry Standards
- Insider transactions are a normal part of corporate governance.
- Comparing Ring's transactions to those of executives at similar biotech companies (e.g., executives at companies like Gilead, Amgen, or Biogen) would provide context on the scale and frequency of such activities.
- The use of a 10b5-1 plan is a common practice among corporate executives to avoid accusations of insider trading.
Stakeholder Impact
- The transactions could have a minor impact on shareholders, depending on their interpretation of insider activity.
- The sale of shares by an executive could be perceived negatively by some investors, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 09/09/2020 | Option vested as to 1/4 of the total shares. |
| 08/09/2023 | Option was fully vested. |
| 11/01/2024 | Earliest transaction date: stock option exercise and sale of shares. |
| 09/30/2029 | Expiration date of Employee Stock Option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.